Wang and colleagues evaluated 330 patients with melanoma treated with PD-1 inhibitors without reporting an association between disease response, disease progression, OS, and use of non-steroidal anti-inflammatory drugs (including aspirin) [56]. This evidence concerns the gene PDCD1 and melanoma.